Posted in Press Releases

Novel, Intranasal Dihydroergotamine Dosed via Precision Olfactory Delivery, or POD™, Device Achieved Primary Outcome of Bioavailability, Safety Study Marks First of Four Impel Clinical Trial Read Outs Planned for 2018 SEATTLE, Feb. 7, 2018  -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today...

Posted in Press Releases

Study to Explore Bioavailability and Safety of Novel, Intranasal Dihydroergotamine Delivered via Precision Olfactory Delivery™ Technology SEATTLE, October 31, 2017 -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the first patient was dosed in the recently-initiated...

Posted in Press Releases

New CEO will lead Impel’s unique CNS pipeline to the clinic and potential commercialization Seattle, WA—October 03, 2017—Impel NeuroPharma, Inc., a Seattle based biotechnology company, announced the appointment of veteran biotech executive Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Impel is developing first-in-class intranasal drug...

Posted in Press Releases

SEATTLE, Feb. 7, 2017 -- Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC. Camargo will be providing end-to-end regulatory consulting and strategic development services for Impel's pipeline of drug-device combination products built...

Posted in Press Releases

Seattle May 4, 2016 -- Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents...

Posted in Press Releases

SEATTLE February 29, 2016 -- The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates...

Posted in Press Releases

Impel raises Series B round to commercialize POD technology platform and Impel’s growing portfolio of enhanced CNS products SEATTLE, October 14, 2015 -- Impel NeuroPharma Inc., (Impel) today announced the first close in its Series B financing round to commercialize the company’s revolutionary Precision Olfactory Delivery (POD) technology for the enhanced...

Categories